Hepatology and Liver Transplantation, Hospital Sírio-Libanês, São Paulo, Brazil.
Hepatology and Liver Transplantation A. C. Camargo Cancer Center, São Paulo, Brazil.
Pediatr Transplant. 2021 Aug;25(5):e13968. doi: 10.1111/petr.13968. Epub 2021 Feb 16.
The treatment of choice for patients with cirrhosis and HPS is LT. The clinical manifestations associated with hypoxemia result in limitations and a poor health-related quality of life of affected patients. The present report aims to study the differences in outcomes between patients with PaO < 50 mm Hg and those with PaO ≥ 50 mm Hg.
This was a retrospective study of 21 patients under 18 years of age conducted from 2001 to 2018; the patients were divided into 2 groups: G1-PaO ≥ 50 mm Hg, 11 patients, and G2-PaO < 50 mm Hg, 10 patients. Demographic, clinical, laboratory, and perioperative data; outcome variables; and post-transplant survival were compared between the groups.
In total, 2/11 (18.2%) patients in G1 and 8/10 (80%) patients in G2 required supplemental oxygen therapy at home (P = .005). Patients in G2 required prolonged MV (median 8.5 days in G2 vs 1 day in G1, P = .015) and prolonged ICU and hospital stays (P = .002 and P = .001, respectively). Oxygen weaning time was longer in G2 (median 127.5 days) than in G1 (median 3 days; P = .004). One (9.1%) patient in G1 and three (30%) patients in G2 died (P = .22). The survival at 90 months was 90.9% in G1 and 70% in G2 (P = .22).
The survival between groups was similar. Patients with very severe HPS required a longer MV time, longer ICU and hospital stays, and a longer O weaning time than those with mild, moderate, or severe HPS.
对于肝硬化合并 HPS 患者,首选治疗方法是 LT。低氧血症相关的临床表现导致患者活动受限和生活质量较差。本报告旨在研究 PaO <50mmHg 和 PaO ≥50mmHg 患者之间结局的差异。
这是一项回顾性研究,纳入 2001 年至 2018 年期间年龄小于 18 岁的 21 例患者;将患者分为 2 组:G1-PaO ≥50mmHg,11 例,G2-PaO <50mmHg,10 例。比较两组患者的人口统计学、临床、实验室和围手术期数据;结局变量;以及移植后生存率。
G1 组中有 2/11(18.2%)例患者和 G2 组中有 8/10(80%)例患者需要家庭补充氧气治疗(P=0.005)。G2 组患者需要更长时间的 MV(中位数 G2 为 8.5 天,G1 为 1 天,P=0.015)和更长的 ICU 和住院时间(P=0.002 和 P=0.001)。G2 组患者的氧脱机时间更长(中位数 127.5 天),G1 组为 3 天(P=0.004)。G1 组中有 1 例(9.1%)患者和 G2 组中有 3 例(30%)患者死亡(P=0.22)。G1 组患者 90 个月的生存率为 90.9%,G2 组为 70%(P=0.22)。
两组之间的生存率相似。与轻度、中度或重度 HPS 患者相比,极重度 HPS 患者需要更长的 MV 时间、更长的 ICU 和住院时间以及更长的氧脱机时间。